Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
Cannara Biotech (TSX: LOVE) reported fiscal Q3 ended May 31, 2026 net revenues of C$31.8M, gross profit before fair value adjustments of C$13.4M (42% margin), adjusted EBITDA of C$8.5M, and operating cash flow of C$5.7M. The company said distribution exceeded 49,000 points and cultivation capacity rose to 14 of 24 grow zones, with more zones planned for 2027.
How this was made
The 30-second read
Why it matters
The combination of record quarterly revenues, maintained profitability, and a faster-than-planned grow-zone activation schedule is likely to re-rate the market’s view of execution and forward capacity. However, the cash flow decline highlights that earnings quality may be partially offset by capex intensity.
Market read
Traders can update models around Cannara’s near-term earnings power and forward production capacity, while monitoring cash flow sensitivity to expansion capex.
What to watch
Gross margin percentage dipped (42% vs 44%) due to product mix, and operating income YTD declined due to higher non-cash share-based compensation and increased sales and marketing spend.
Background
Cannara is a vertically integrated Canadian cannabis producer, reporting fiscal Q3 ended May 31, 2026, with updates on distribution footprint and cultivation capacity at its Valleyfield facility.
Ticker impact
Cannara (LOVE) reported Q3 results with $31.8M net revenues, $8.5M adjusted EBITDA, and expanded distribution plus activated grow zones.
Near-term bias positive on earnings quality and capacity visibility, with some profit-taking risk from lower free cash flow.
The article discloses multiple fresh, decision-relevant datapoints: quarterly financials, distribution penetration, grow-zone activations, and forward capacity targets for fiscal 2027.
Market effects
Signals strength in Canadian cannabis retail penetration and execution on capacity expansion, potentially supporting sector read-through on profitable scaling.
Focuses on Québec-based production scaling, which may reinforce investor confidence in regional operators’ throughput growth.
Limited direct global linkage, but the mention of an international supply agreement can modestly improve cross-border demand expectations.
Counterpoint
Despite record profitability, operating cash flow and free cash flow fell year over year, implying near-term cash generation pressure from ongoing expansion.
Key entities
- companyCannara Biotech Inc.
Reported record Q3 revenues and continued profitability, expanded national distribution, and accelerated grow-zone activations with fiscal 2027 capacity targets.
- facilityValleyfield facility
Québec cultivation/processing site where two additional grow zones were activated in Q3 2026, bringing total zones in production to 14 of 24.
- acquisition_targetMedican Organic Inc.
Cannara stated it completed the acquisition as part of strategic priorities mentioned in management commentary.
- technology_partnerBlue River
Cannara secured exclusive Canadian rights to Blue River’s Ampersand live rosin infusion technology.
- supply_partnerCuraleaf
Cannara entered its first long-term international supply agreement with Curaleaf.
